REGENXBIO Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Trading Plans
The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended December 31, 2024, each of which is intended to satisfy the affirmative defense of Rule 10b5-1(c) (Rule 10b5-1 Plan), were as follows:
| Rule 10b5-1 Trading Plan · Aggregate # of | ||||||
|---|---|---|---|---|---|---|
| Provides for · Securities to be | ||||||
| Name | Title | Action | Date Adopted | Expiration Date | Purchase/Sale | Purchased/Sold (b) |
| David C. Stump | Director | Adoption | 11/21/2024 | 6/1/2026 | Sale | 37,500 |
| Stephen Pakola, M.D. | Executive Vice President, Chief Medical Officer | Adoption | 12/20/2024 | 12/31/2025 | Sale | 260,368 |
| Entities affiliated with Allan M. Fox (a) | Director | Adoption | 12/21/2024 | 3/31/2027 | Sale | 1,441,231 |
| Patrick J. Christmas | Executive Vice President, Chief Legal Officer | Adoption | 12/26/2024 | 1/4/2027 | Sale | 235,400 |
(a)
Entities affiliated with Allan M. Fox, a director of the Company, include AMF Family Gift Trust LLC, AMF Gift Trust LLC, HBF Gift Trust LLC and Quaker Gray LLC (collectively, the Fox LLCs). Mr. Fox maintains voting and investment control over the shares held by the Fox LLCs in his capacity as manager of the Fox LLCs.
(b)
The aggregate number of shares in this column includes shares that may be forfeited or withheld to satisfy exercise price and tax withholding obligations at the time of vesting.
Other than as described above, during the three months ended December 31, 2024, none of ourdirectors or Section 16 reporting officers adopted orterminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC's Regulation S-K).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.